Amgen falls after obesity study results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/12/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Amgen (AMGN) PT Raised to $352 at Leerink Partners
November 27, 2024 6:19 AM ESTLeerink Partners analyst David Risinger raised the price target on Amgen (NASDAQ: AMGN) to $352.00 (from $305.00) while maintaining a Market Perform rating.
The analyst comments "Bottom Line: We are lowering our PT from $352 (18x 2025E EPS of $19.55) to $305 (15x 2025E EPS of $20.33) and maintaining our Market Perform rating. We lowered our 5- yr (25-30) CAGR EPS from 8% to 4%, largely driven by higher investment spending assumptions. MariTides Ph2 results... More
Piper Sandler Reiterates Overweight Rating on Amgen (AMGN)
November 26, 2024 10:37 AM ESTPiper Sandler analyst Christopher Raymond reiterated an Overweight rating and $344.00 price target on Amgen (NASDAQ: AMGN).
The analyst comments "Remain OW rated on AMGN shares and would expect the stock to eventually recover from todays initial sell-off on AMGNs... More
